100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
110671-78-814- Hydroxy Clarithromycin
● Under development
| Catalogue No.: | VE008176 |
|---|---|
| CAS No.: | 110671-78-8 |
| Mol. Formula: | C38H69NO14 |
| Mol. Weight: | 763.96 g/mol |
Additional information on CAS 110671-78-8
Parent drug
ClarithromycinIUPAC Name
(3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-6-(((2S, 3R, 4S, 6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-12, 13-dihydroxy-4-(((2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-14-(1-hydroxyethyl)-7-methoxy-3, 5, 7, 9, 11, 13-hexamethyloxacyclotetradecane-2, 10-dioneSynonyms
N/ADescription
14 Hydroxy Clarithromycin (CAS No: 110671-78-8) is a metabolite of clarithromycin. Clarithromycin is an acid-stable and orally taken macrolide antimicrobial drug and is structurally similar to erythromycin. It has a broad spectrum of antimicrobial activity and blocks an array of Gram-positive and Gram-negative organisms especially atypical pathogens and some anaerobes.References
Baumann, Michaela, et al. “Aquatic Toxicity of the Macrolide Antibiotic Clarithromycin and Its Metabolites.†Chemosphere, vol. 120, Feb. 2015, pp. 192–98, https://doi.org/10.1016/j.chemosphere.2014.05.089. Peters, David H., and Stephen P. Clissold. “Clarithromycin.†Drugs, vol. 44, no. 1, July 1992, pp. 117–64, https://doi.org/10.2165/00003495-199244010-00009.Request a Quote
"*" indicates required fields
Other products related to Clarithromycin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Clarithromycin
CAS No. 81103-11-9
Cat No. VE0027697
